Barclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Barclays analyst Glen Santangelo reinstates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight and announces $110 price target.
Barclays analyst Glen Santangelo reinstates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight and announces $110 price target.